A61P 9 - Drugs for disorders of the cardiovascular system

Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
12/2006
12/28/2006	WO2006138214A1 Nanoparticulate clopidogrel and aspirin combination formulations
12/28/2006	WO2006138195A1 Macrocyclic heterocyclic aspartyl protease inhibitors
12/28/2006	WO2006138192A1 Aspartyl protease inhibitors
12/28/2006	WO2006137797A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137796A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137795A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137794A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
12/28/2006	WO2006137793A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137792A1 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
12/28/2006	WO2006137772A1 New physical form of n,n´- disubstituted oxabispidines
12/28/2006	WO2006137527A1 Thiazole derivative
12/28/2006	WO2006137490A1 Therapeutic agent for restenosis
12/28/2006	WO2006137469A1 Metabotropic glutamate receptor activator
12/28/2006	WO2006137466A1 Pharmaceutical composition
12/28/2006	WO2006137465A1 Nitrogenated heterocyclic derivative
12/28/2006	WO2006137450A1 Crystal of phenylalanine derivative, process for producing the same and use thereof
12/28/2006	WO2006137435A1 Agonist to g protein-coupled receptor g2a and method of screening g2a activity controller
12/28/2006	WO2006137421A1 Agent for topical administration
12/28/2006	WO2006137222A1 Method for control of drug elution rate and composition for coating of drug-eluting stent
12/28/2006	WO2006136821A1 Pharmaceutical compounds
12/28/2006	WO2006136305A1 SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM
12/28/2006	WO2006136304A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
12/28/2006	WO2006136114A1 Amniotic cells and methods for use thereof
12/28/2006	WO2006108670A3 Use of cd25 antibodies in immunotherapy
12/28/2006	WO2006087420A3 A method for treating heart failure
12/28/2006	WO2006087419A3 A method for administering levosimendan
12/28/2006	WO2006082409A8 Tricyclic cytoprotective compounds
12/28/2006	WO2005094796A3 Methods for interfering with fibrosis
12/28/2006	US20060293543 Isolation of lutein from alfalfa
12/28/2006	US20060293519 Method for producing cyclic diamine derivative or salt thereof
12/28/2006	US20060293507 Crystallization of IGF-1
12/28/2006	US20060293391 Use of 15-deoxyspergualin for the treatment of hyperreactive inflammatory diseases and autoimmune diseases
12/28/2006	US20060293375 Crystal of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid; has chymase inhibitory activity in living body and can be used as a preventive and/or remedy for inflammatory diseases, allergic diseases, respiratory tract diseases, circulatory diseases, or bone metabolic diseases
12/28/2006	US20060293348 CSBP/p38 kinase inhibitor; antiinflammatory agent; inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, rheumatoid arthritis; 8-(2,4,6-trifluorophenyl)-4-(2,4-difluorophenyl)-2-(2-hydroxy-1-hydroxymethylethylamino)-8H-pyridio[2,3]pyrimidin-7-one
12/28/2006	US20060293347 Pharmaceutically active compounds
12/28/2006	US20060293335 Riboflavin derivative and its manufacture and uses
12/28/2006	US20060293326 2-Heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/28/2006	US20060293252 such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics
12/28/2006	US20060293225 Gmg-2 polynucleotides and polypeptides and uses thereof
12/28/2006	US20060293219 Methods of treating diabetes mellitus
12/28/2006	US20060292673 For degradation of glycosaminoglycans; inhibiting angiogenesis and cellular proliferation; treating cancer, neurodegenerative disease, atherosclerosis and microbial infection
12/28/2006	US20060292655 2-O sulfatase compositions and methods of analyzing therewith
12/28/2006	US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases
12/28/2006	US20060292249 Oral compositions for the treatment of cellulite
12/28/2006	US20060292131 Chondrocyte Therapeutic Delivery System
12/28/2006	US20060292130 2-O sulfatase nucleic acid compositions
12/28/2006	DE102006023178A1 New solid crystalline telmisartan form A useful for preparation of pharmaceutical composition for treatment of hypertension
12/28/2006	DE102005028845A1 New substituted pyrrolidin-2-ones, piperidin-2-ones and isothiazolidine-1,1-dioxides useful for treating e.g. dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, breast cancer and heart failure
12/28/2006	CA2620946A1 Amniotic cells and methods for use thereof
12/28/2006	CA2613249A1 Crystals of phenylalanine derivatives, production method thereof and use thereof
12/28/2006	CA2612922A1 2-(phenylamino)benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels
12/28/2006	CA2612384A1 Nanoparticulate azelnidipine formulations
12/28/2006	CA2611741A1 Nanoparticulate clopidogrel and aspirin combination formulations
12/28/2006	CA2611142A1 Anti-hypercholesterolemic compounds
12/28/2006	CA2610829A1 The preparation and use of compounds as aspartyl protease inhibitors
12/28/2006	CA2610828A1 Heterocyclic aspartyl protease inhibitors, preparation and use thereof
12/28/2006	CA2610812A1 Aspartyl protease inhibitors
12/28/2006	CA2610326A1 Substituted pyrr0lidin-2-0nes , piperidin-2-0nes and isothiazolidine-1, 1-dioxides, their use as kv1.5 potassium channel blockers and pharmaceutical preparations comprising them
12/28/2006	CA2610102A1 New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
12/28/2006	CA2610075A1 Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
12/28/2006	CA2610036A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609994A1 New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
12/28/2006	CA2609993A1 Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609990A1 New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
12/28/2006	CA2609562A1 Macrocyclic heterocyclic aspartyl protease inhibitors
12/27/2006	EP1736775A1 Novel ligand of g protein coupled receptor protein and use thereof
12/27/2006	EP1736474A1 Piperidine derivative
12/27/2006	EP1736470A2 Pyrimidine derivatives as CB2 cannabinoid receptor modulators
12/27/2006	EP1736469A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol
12/27/2006	EP1736467A1 Novel sulfonamide derivative
12/27/2006	EP1736464A1 Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease
12/27/2006	EP1736206A1 Physiologically active composition and process for producing the same
12/27/2006	EP1736173A1 Damaged tissue therapeutic agent and therapeutic method
12/27/2006	EP1736168A1 Protease inhibitor and preventives or remedies for diseases
12/27/2006	EP1736155A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
12/27/2006	EP1736149A2 Astaxanthin-containing agent for lowering neutral fat concentration in blood
12/27/2006	EP1735320A1 Compounds and methods for treating dyslipidemia
12/27/2006	EP1735270A1 Diamino alcohols and their use as renin inhibitors
12/27/2006	EP1735055A1 Method of reducing c-reactive protein using growth hormone secretagogues
12/27/2006	EP1734973A2 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
12/27/2006	EP1734969A2 Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (ryr2) and uses thereof
12/27/2006	EP1734930A2 Low dose pharmaceutical products
12/27/2006	EP1734821A2 Activators of hexosamine biosynthesis as inhibitors of injury induced by ischemia or hemorrhagic shock
12/27/2006	EP1653963B1 Nasal pharmaceutical piribedil composition
12/27/2006	EP1443925B1 Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
12/27/2006	EP1427423B1 Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
12/27/2006	EP1417180B1 Preparation of aminopyrimidine compounds
12/27/2006	EP1406876B1 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors
12/27/2006	EP1392276B1 Potentiation of therapeutic effects of polyunsaturated fatty acids
12/27/2006	EP1379515B1 Lipid lowering biphenylcarboxamides
12/27/2006	EP1368317B1 Tryptase inhibitors
12/27/2006	EP1358209B1 Crystallization of igf-1
12/27/2006	EP1354047B1 Methods for screening compounds that modulate lipid metabolism
12/27/2006	EP1345895B1 Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
12/27/2006	EP1332372B1 Net, a transcription factor of the tcf family, as regulator of angiogenic factor expression
12/27/2006	EP1299374B1 Novel non-psychotropic cannabinoids
12/27/2006	EP1284717B1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
12/27/2006	EP1226144B1 Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
12/27/2006	EP1117437B1 Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
12/27/2006	EP1073739B1 Cd40-interacting and traf-interacting proteins

1 ... 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 ... 1595